162 related articles for article (PubMed ID: 26995694)
1. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
Hong S; Rybicki L; Abounader D; Bolwell BJ; Dean R; Gerds AT; Hamilton BK; Hill BT; Jagadeesh D; Kalaycio M; Liu HD; Pohlman B; Sobecks R; Majhail NS
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1141-1144. PubMed ID: 26995694
[TBL] [Abstract][Full Text] [Related]
2. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.
Hong S; Rybicki L; Abounader DM; Bolwell BJ; Dean R; Gerds AT; Hamilton BK; Hill BT; Jagadeesh D; Kalaycio M; Liu HD; Pohlman B; Sobecks R; Majhail NS
Bone Marrow Transplant; 2016 Sep; 51(9):1191-6. PubMed ID: 27111046
[TBL] [Abstract][Full Text] [Related]
3. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.
Dhakal B; Nelson A; Guru Murthy GS; Fraser R; Eastwood D; Hamadani M; Pasquini M; D'Souza A; Hari P
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):165-172. PubMed ID: 28159578
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract][Full Text] [Related]
5. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
6. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
7. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.
Fu S; Rybicki L; Abounader D; Andresen S; Bolwell BJ; Dean R; Gerds A; Hamilton BK; Hanna R; Hill BT; Jagadeesh D; Kalaycio ME; Liu HD; Pohlman B; Sobecks RM; Majhail NS
Bone Marrow Transplant; 2015 Oct; 50(10):1326-30. PubMed ID: 26191953
[TBL] [Abstract][Full Text] [Related]
8. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
9. Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma.
Rahman S; Rybicki L; Ky Hamilton B; Pohlman B; Jagadeesh D; Cober E; Kalaycio M; Dean R; Sobecks R; Mossad SB; Majhail NS
Transpl Infect Dis; 2019 Aug; 21(4):e13114. PubMed ID: 31102556
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
11. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW; Garderet L; Kröger N
Br J Haematol; 2015 Nov; 171(4):453-62. PubMed ID: 26213240
[TBL] [Abstract][Full Text] [Related]
12. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents.
Al-Hamadani M; Hashmi SK; Go RS
Am J Hematol; 2014 Aug; 89(8):825-30. PubMed ID: 24799343
[TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
14. Older patients with myeloma derive similar benefit from autologous transplantation.
Sharma M; Zhang MJ; Zhong X; Abidi MH; Akpek G; Bacher U; Callander NS; Dispenzieri A; Freytes CO; Fung HC; Gale RP; Gasparetto C; Gibson J; Holmberg LA; Kindwall-Keller TL; Klumpp TR; Krishnan AY; Landau HJ; Lazarus HM; Lonial S; Maiolino A; Marks DI; Mehta P; Mikhael Med JR; Nishihori T; Olsson R; Ramanathan M; Roy V; Savani BN; Schouten HC; Scott E; Tay J; To LB; Vesole DH; Vogl DT; Hari P
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1796-803. PubMed ID: 25046833
[TBL] [Abstract][Full Text] [Related]
15. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
Hari PN; Majhail NS; Zhang MJ; Hassebroek A; Siddiqui F; Ballen K; Bashey A; Bird J; Freytes CO; Gibson J; Hale G; Holmberg L; Kamble R; Kyle RA; Lazarus HM; LeMaistre CF; Loberiza F; Maiolino A; McCarthy PL; Milone G; Omondi N; Reece DE; Seftel M; Trigg M; Vesole D; Weiss B; Wiernik P; Lee SJ; Rizzo JD; Mehta P
Biol Blood Marrow Transplant; 2010 Mar; 16(3):395-402. PubMed ID: 19922808
[TBL] [Abstract][Full Text] [Related]
16. Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review.
Lupak O; Xiaoxia H; Xie P; Thanikachalam K; Jabbour-Aida H; Farhan S; Emole J
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e680-e685. PubMed ID: 34148850
[TBL] [Abstract][Full Text] [Related]
17. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
Costa LJ; Huang JX; Hari PN
Biol Blood Marrow Transplant; 2015 Apr; 21(4):701-6. PubMed ID: 25555447
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
20. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
